Trends in lifetime risk and years of potential life lost from diabetes in the United States, 1997-2018.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
03
2022
accepted:
09
05
2022
entrez:
24
5
2022
pubmed:
25
5
2022
medline:
27
5
2022
Statut:
epublish
Résumé
Both incidence and mortality of diagnosed diabetes have decreased over the past decade. However, the impact of these changes on key metrics of diabetes burden-lifetime risk (LR), years of potential life lost (YPLL), and years spent with diabetes-is unknown. We used data from 653,811 adults aged ≥18 years from the National Health Interview Survey, a cross-sectional sample of the civilian non-institutionalized population in the United States. LR, YPLL, and years spent with diabetes were estimated from age 18 to 84 by survey period (1997-1999, 2000-2004, 2005-2009, 2010-2014, 2015-2018). The age-specific incidence of diagnosed diabetes and mortality were estimated using Poisson regression. A multistate difference equation accounting for competing risks was used to model each metric. LR and years spent with diabetes initially increased then decreased over the most recent time periods. LR for adults at age 20 increased from 31.7% (95% CI: 31.2-32.1%) in 1997-1999 to 40.7% (40.2-41.1%) in 2005-2009, then decreased to 32.8% (32.4-33.2%) in 2015-2018. Both LR and years spent with diabetes were markedly higher among adults of non-Hispanic Black, Hispanic, and other races compared to non-Hispanic Whites. YPLL significantly decreased over the study period, with the estimated YPLL due to diabetes for an adult aged 20 decreasing from 8.9 (8.7-9.1) in 1997-1999 to 6.2 (6.1-6.4) in 2015-2018 (p = 0.02). In the United States, diabetes burden is declining, but disparities by race/ethnicity remain. LR remains high with approximately one-third of adults estimated to develop diabetes during their lifetime.
Sections du résumé
BACKGROUND
Both incidence and mortality of diagnosed diabetes have decreased over the past decade. However, the impact of these changes on key metrics of diabetes burden-lifetime risk (LR), years of potential life lost (YPLL), and years spent with diabetes-is unknown.
METHODS
We used data from 653,811 adults aged ≥18 years from the National Health Interview Survey, a cross-sectional sample of the civilian non-institutionalized population in the United States. LR, YPLL, and years spent with diabetes were estimated from age 18 to 84 by survey period (1997-1999, 2000-2004, 2005-2009, 2010-2014, 2015-2018). The age-specific incidence of diagnosed diabetes and mortality were estimated using Poisson regression. A multistate difference equation accounting for competing risks was used to model each metric.
RESULTS
LR and years spent with diabetes initially increased then decreased over the most recent time periods. LR for adults at age 20 increased from 31.7% (95% CI: 31.2-32.1%) in 1997-1999 to 40.7% (40.2-41.1%) in 2005-2009, then decreased to 32.8% (32.4-33.2%) in 2015-2018. Both LR and years spent with diabetes were markedly higher among adults of non-Hispanic Black, Hispanic, and other races compared to non-Hispanic Whites. YPLL significantly decreased over the study period, with the estimated YPLL due to diabetes for an adult aged 20 decreasing from 8.9 (8.7-9.1) in 1997-1999 to 6.2 (6.1-6.4) in 2015-2018 (p = 0.02).
CONCLUSION
In the United States, diabetes burden is declining, but disparities by race/ethnicity remain. LR remains high with approximately one-third of adults estimated to develop diabetes during their lifetime.
Identifiants
pubmed: 35609056
doi: 10.1371/journal.pone.0268805
pii: PONE-D-22-09393
pmc: PMC9129010
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0268805Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Phys Act Health. 2009;6 Suppl 1:S18-27
pubmed: 19998846
JAMA. 2014 Sep 24;312(12):1218-26
pubmed: 25247518
J Am Stat Assoc. 2007 Fall;102(480):1199-1211
pubmed: 26279593
Popul Health Metr. 2016 Dec 15;14:48
pubmed: 27978825
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Lancet Diabetes Endocrinol. 2021 Apr;9(4):203-211
pubmed: 33636102
J Gen Intern Med. 2020 May;35(5):1427-1434
pubmed: 31898135
Curr Diab Rep. 2013 Dec;13(6):814-23
pubmed: 24037313
JAMA. 2019 Sep 24;322(12):1178-1187
pubmed: 31550032
Nutrients. 2020 Aug 04;12(8):
pubmed: 32759636
Int J Clin Pract. 2021 Apr;75(4):e13980
pubmed: 33752297
Reprod Sci. 2010 Jun;17(6):511-31
pubmed: 20460551
N Engl J Med. 2018 Apr 05;378(14):1302-1312
pubmed: 29617589
Diabetologia. 2008 Dec;51(12):2179-86
pubmed: 18810385
MMWR Morb Mortal Wkly Rep. 2019 Jun 14;68(23):513-518
pubmed: 31194722
J Epidemiol. 2018 Nov 5;28(11):465-469
pubmed: 29731478
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):161-165
pubmed: 32053581
Diabetologia. 2014 Dec;57(12):2465-74
pubmed: 25226881
Lancet. 2018 Jun 16;391(10138):2430-2440
pubmed: 29784146
Lancet Diabetes Endocrinol. 2014 Nov;2(11):867-74
pubmed: 25128274
Epidemiology. 1990 Jul;1(4):322-9
pubmed: 2083312
JAMA. 2020 Sep 22;324(12):1208-1210
pubmed: 32857101
Diabetes Metab Syndr Obes. 2014 Oct 20;7:487-94
pubmed: 25349480
Diabetologia. 2008 Dec;51(12):2187-96
pubmed: 18815769
JAMA. 2019 Nov 26;322(20):1996-2016
pubmed: 31769830
BMJ Open Diabetes Res Care. 2019 May 28;7(1):e000657
pubmed: 31245008